Ways2Capital Reviews : Strides Shasun Gets Final Approval For gTamiflu

Strides Shasun has announced that it’s wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received final USFDA approval for Tamiflu (Oseltamivir Phosphate Capsules). Tamiflu is a brand of Hoffmann-La Roche, Inc. gTamiflu approval is a positive news for Strides Shasun.

Oseltamivir Phosphate Capsules registered a significant volume growth in 2017 due to one of the worst flu seasons in the US. US market for Oseltamivir Phosphate Capsules was approximately $725mn as per IQVIA MAT April 2018 data. Natco Pharma is also selling gTamiflu in the US market for over a year.

gTamiflu will be manufactured at the Strides Shasun’s Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market. Strides currently has 75 cumulative ANDA filings with USFDA, of which 48 ANDAs have been approved as of date and 27 are pending approval.

The company’s Q4FY18 revenue was impacted due to delay in the gTamiflu approval. Besides the aggressive pricing by its competitors in two generic products also hurt the company’s US sales and profitability in Q4FY18.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai